AtaCor enrolls first patient in ALARION-EV ICD study

The trial will test AtaCor’s investigational Atala lead with Abbott’s investigational EV-ICD pulse generator in up to 280 patients across as many as 40 sites in the United States and the Netherlands.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.